V Wealth Advisors’s Pacira BioSciences PCRX Stock Holding History

V Wealth Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-135	Closed	-$6K	–	558
2017 Q2	$6K	Buy	+135	New	+$6.26K	﹤0.01%	636

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

V Wealth Advisors's PCRX Position: Q3 2017 in Review

V Wealth Advisors sold out of Pacira BioSciences (PCRX) in Q3 2017, closing a stake of 135 shares — an estimated $6K sold.

V Wealth Advisors first reported a position in PCRX in Q2 2017 and held it in 1 quarter. The position peaked at $6K in Q2 2017. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2017.

V Wealth Advisors reported no remaining Pacira BioSciences position as of Q3 2017 after selling out during the quarter.
V Wealth Advisors sold 135 Pacira BioSciences shares in Q3 2017, an estimated $6K.
V Wealth Advisors first reported a position in Pacira BioSciences in Q2 2017 and held it in 1 quarter.
V Wealth Advisors's Pacira BioSciences position peaked at $6K in Q2 2017.
180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2017.

Based on V Wealth Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.